Risk of myelodysplastic syndrome/acute leukemia with sequential capecitabine/temozolomide and 177Lu-dotatate

#3555

Introduction: The treatment landscape for neuroendocrine tumors includes alkylating-agent chemotherapy and peptide receptor radiotherapy (PRRT) with 177Lu-Dotatate. The risk of MDS/AML associated with 177Lu-Dotatate is approximately 2-3%. Several small prior studies have suggested substantially higher rates of MDS/AML (approximately 10%) in patients who have also received alkylating agent chemotherapy with streptozocin or temozolomide, either combined with PRRT or sequentially.

Aim(s): To determine whether sequential treatment with alkylating chemotherapy and PRRT poses an increased risk of developing MDS/AML.

Materials and methods: Retrospective study of all patients with advanced NENs treated at the Moffitt Cancer Center between 1/2008 and 9/2019 who received treatment with CAPTEM.

Conference:

Presenting Author:

Authors: Al-Toubah T, Pelle E, Strosberg J,

Keywords: captem, PRRT, mds, aml,